Patents by Inventor William E. Sweeney

William E. Sweeney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9511072
    Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: December 6, 2016
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: William E. Sweeney, Ellis D. Avner, Richard J. Roman
  • Publication number: 20140329811
    Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
    Type: Application
    Filed: June 12, 2014
    Publication date: November 6, 2014
    Inventors: William E. Sweeney, Ellis D. Avner, Richard J. Roman
  • Patent number: 8846764
    Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: September 30, 2014
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: William E. Sweeney, Ellis D. Avner, Richard J. Roman
  • Publication number: 20080167382
    Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
    Type: Application
    Filed: September 13, 2007
    Publication date: July 10, 2008
    Inventors: William E. Sweeney, Ellis D. Avner, Richard J. Roman
  • Patent number: 6952214
    Abstract: A graphics system comprising a plurality of rendering pipelines and a scheduling network. Each rendering pipeline couples to the scheduling network, and includes a media processor, a rendering unit and a memory. A communication bus may couple the scheduling network and the memory of each rendering pipeline. The media processor in each rendering pipeline may direct the saving of state information of the corresponding rendering pipeline to the corresponding memory in response to receiving a corresponding context switch indication. A first of the media processors initiates the transfer of a resume token to the scheduling network through the corresponding rendering pipeline if the context switch occurs during an ordered processing mode. The scheduling network unblocks one or more rendering pipelines other than the first rendering pipeline in response to receiving the resume token.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: October 4, 2005
    Assignee: Sun Microsystems, Inc.
    Inventors: Nathaniel David Naegle, William E. Sweeney, Jr., Wayne A. Morse
  • Publication number: 20040008200
    Abstract: A graphics system comprising a plurality of rendering pipelines and a scheduling network. Each rendering pipeline couples to the scheduling network, and includes a media processor, a rendering unit and a memory. A communication bus may couple the scheduling network and the memory of each rendering pipeline. The media processor in each rendering pipeline may direct the saving of state information of the corresponding rendering pipeline to the corresponding memory in response to receiving a corresponding context switch indication. A first of the media processors initiates the transfer of a resume token to the scheduling network through the corresponding rendering pipeline if the context switch occurs during an ordered processing mode. The scheduling network unblocks one or more rendering pipelines other than the first rendering pipeline in response to receiving the resume token.
    Type: Application
    Filed: July 12, 2002
    Publication date: January 15, 2004
    Inventors: Nathaniel David Naegle, William E. Sweeney, Wayne A. Morse